TERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today abstracts of research on regimens containing either one of Enanta’s two protease inhibitors for hepatitis C virus (HCV) identified and developed in its ongoing collaboration with AbbVie, have been accepted for presentation at The International Liver Congress (ILC), which is the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna April 22-26, 2015.
Help employers find you! Check out all the jobs and post your resume.
